TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Patients registered in the Zhejiang Stroke Quality Control Centre (ZSQCC) platform from Jan 2017 to Mar 2020~* \> 80 years of age~* Diagnosed with AIS at admission~* Arrived or admitted to the hospital within 4.5 hours of symptom onset~* If treated with IV rt-PA: received IV rt-PA within 4.5 hours of symptom onset~Exclusion criteria:~* Documented Intravenous Thrombolysis (IVT) contraindication except age to IV rt-PA treatment according to the Summary of Product Characteristics (SmPC)~* Missing any one of the key data (age, gender, baseline National Institutes of Health Stroke Scale \[NIHSS\], time of symptom onset, time of hospital arrival or admission, IVT or not, time of IV rt-PA treatment)~* Received thrombolysis agents other than rt-PA (urokinase, tenecteplase, recombinant plasminogen activator, prourokinase, streptokinase)~* Received endovascular treatment~* Received IV rt-PA after 4.5 hours of symptom onset

- Gender: ALL
- Minimum Age: 80 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV rt-PA cohort (Type: None): Acute Ischaemic Stroke (AIS) patients aged \> 80 years who received intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) (Alteplase) within 4.5 hours of symptom onset
- Non-reperfusion cohort (Type: None): Acute Ischaemic Stroke (AIS) patients aged \> 80 years who arrived or were admitted to the hospital within 4.5 hours of symptom onset and did not receive any reperfusion treatments

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women ≥ 18 years of age;~* Clinical diagnosis of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE);~* Anticoagulant treatment completed~* No recurrence of Venous Thromboembolism (VTE)~Exclusion Criteria:~* Subjects with indications for long-term treatment with a vitamin K antagonist~* Active bleeding or high risk for serious bleeding~* Short life expectancy~* Uncontrolled high blood pressure~* Impaired kidney or liver function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 2.5 mg
- 2 (Type: EXPERIMENTAL): 5.0 mg
- 3 (Type: ACTIVE_COMPARATOR): 0 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Flaps for Root Coverage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting Miller class I or II gingival recession in the maxillary canines or premolars~* Visible cemento-enamel junction (CEJ) with pulp vitality;~* Patients presenting no signs of active periodontal disease and full-mouth plaque and bleeding score ≤20%;~* Patients older than 18 years old; probing depth ˂3 mm in the included teeth;~* Patients who agreed to participate and signed an informed consent form.~Exclusion Criteria:~* Patients presenting systemic problems that would contraindicate the surgical procedure;~* Patients taking medications known to interfere with the wound healing process or that contraindicate the surgical procedure;~* Smokers or pregnant women;~* Patients who underwent periodontal surgery in the area of interest;~* Patients with orthodontic therapy in progress.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- CAF plus connective tissue graft (Type: ACTIVE_COMPARATOR): CAF treatment was performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision was made to unite the releasing incisions and the flap was raised beyond the mucogingival junction (MGJ) in split-full-split thickness. The connective tissue graft was removed from the palate according to Bruno technique (1994) and sutured in position. Sling sutures were placed to stabilize the flap in a coronal position 2 mm above the CEJ, followed by interrupted sutures to close the releasing incisions.
- Tunnel plus connective tissue graft (Type: EXPERIMENTAL): The tunnel flap was performed according to Zuhr et al., 2007. Following initial sulcular incisions, spit thickness flap was prepared using specific tunneling knives beyond the mucogingival junction and until flap gain mobility. The flap was laterally extended to adjacent papillae that were carefully detached by means of a full-thickness preparation. The connective tissue graft was insert into the tunnel. Sling sutures were performed involving the flap and graft to coronally cover 2 mm above the CEJ.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~- Women with locally advanced, recurrent, or metastatic breast cancer along with confirmation of estrogen-receptor positive (ER+). Measurable disease defined as at least one lesion ≥ 10 mm by CT or MRI that can be accurately measured in at least one dimension (CT scan slice thickness ≤ 5 mm) OR • Bone lesions: lytic or mixed (lytic + blastic) in the absence of measurable disease as defined above.~Key Exclusion Criteria:~- Patients who received more than one chemotherapy line. Patients with only non-measurable lesions other than lytic or mixed (lytic and blastic) bone metastasis.Previous treatment with exemestane, mTOR inhibitors, PI3K inhibitors or AKT inhibitors.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Capecitabine 1250 mg/m2 (Type: EXPERIMENTAL): Capecitabine (1250 mg/m2 twice daily) for two weeks, followed by one week rest period in 3-weeks cycles (investigational arm).
- Everolimus 10 mg (Type: EXPERIMENTAL): Everolimus (10 mg daily) (investigational arm).
- Everolimus 10 mg + Exemestane 25 mg (Type: ACTIVE_COMPARATOR): Everolimus (10 mg daily) with Exemestane (25 mg daily) (control arm).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Effects of Food and Morning Versus Evening on Single and Multiple Doses of ONO-5334 in Healthy Post Menopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy caucasian women aged between 55 to 75 years inclusive~* Subjects weighing at least 50 kg with mass index between 19 to 30 kg/m2 inclusive~* Subjects who have been amenorrhoeic for at least 5 years.~* Subjects who are confirmed at Screening Visit to have oestradiol and follicle stimulating hormone (FSH) levels consistent with menopause~Exclusion Criteria:~* Subjects who have a clinically relevant history or presence of any clinically significant disease or disorder~* Subjects who have a clinically relevant history of insomnia or sleep disorders

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- E1 (Type: EXPERIMENTAL): ONO-5334
- E2 (Type: EXPERIMENTAL): ONO-5334

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Effectiveness and Complications of Catheter Lock Solutions in Non-tunneled Hemodialysis Catheters

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients over 18 years who assign consent will be included~Exclusion Criteria:~* patients less than 18 years of age~* Patients with active arterial or venous thrombosis problems~* Thrombocytopenic patients~* Patients with hypercoagulable states~* Patients with contraindications to heparin usage

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Sodium bicarbonate Arm (Type: ACTIVE_COMPARATOR): In this arm, the catheter lock solution is sodium bicarbonate
- Heparin arm (Type: ACTIVE_COMPARATOR): In this arm, classic heparin will be used as a reference catheter lock solution (standard lock solution)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient meets the DSM-IV criteria for schizophrenia~* Patient has a PANSS total score at screening of 60 to 100, inclusive~* Patient must, in the opinion of the investigator, benefit from treatment with paliperidone ER or olanzapine~* Patients on lipid-lowering therapy must be on a stable dose for at least 4 weeks for statins, niacin, ezetimibe and resins or for at least 12 weeks for fibrates~* Female patients must be postmenopausal (for at least 1 year), surgically sterile, abstinent, or, if sexually active, be practicing and effective method of birth control (e.g. prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study~* Women of child-bearing potential must have a negative urine pregnancy test at screening~* Patient is healthy on the basis of a physical examination and vital signs at screening~Exclusion Criteria:~* Patient has previously been treated with paliperidone ER, olanzapine, or clozapine within the past 6 months or has never been treated with an antipsychotic before~* Treatment with a depot antipsychotic within the past 3 months~* Treatment with a mood stabilizer or a recently initiated antidepressant (\<= 3 months)~* Patient has abnormal fasting plasma glucose (\> 126 mg/dL) or fasting triglycerides (TG) levels (\> 400 mg/dL) at screening~* Relevant history of any significant and/or unstable cardiovascular, respiratory, neurologic (including seizures or significant cerebrovascular), renal, hepatic, endocrine, or immunologic diseases, including recent or present clinically relevant laboratory abnormalities (as deemed by the investigator)~* History or current symptoms of tardive dyskinesia~* History of neuroleptic malignant syndrome~* Pregnant or breast-feeding female

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): paliperidone ER 6-mg or 9-mg tablet once daily flexible dosing for 6 months
- 002 (Type: ACTIVE_COMPARATOR): olanzapine 10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Efficacy of Golimumab in Chinese Patients With Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Have a diagnosis of definite akylosing spondylitis for at least 3 months~* Have symptoms of active disease at screening and at baseline~* no active infections~Exclusion Criteria:~* Have other inflammatory diseases that might confound the evaluations of benefit from the golimumab therapy~* Have complete ankylosis of the spine~* Have a history of latent or active granulomatous infection~* Have had a serious infection, or have been hospitalized for an infection, or have been treated with intravenous (IV) antibiotics for an infection within 2 months prior to first administration of study agent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: EXPERIMENTAL): None
- Golimumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ertapenem for Initial Empirical Treatment of Third Generation Cephalosporin Resistant Enterobacteriaceae Bacteremia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults, either sex, ages 18 years or above~* Patients with 3GCRE bacteremia~* Patients admitted to any of the study sites~Exclusion Criteria:~* Discontinuation of antibiotic due to transition to hospice care~* Polymicrobial bacteremia~* Empirical antibiotic after 24 hours of first evidence of bacteremia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Ertapenem (Type: None): Patients who received ertapenem as an empirical antibiotic
- Other carbapenems (Type: None): Patients who received carbapenems other than ertapenem as an empirical antibiotic

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion criteria:~* Subject had successfully completed either Protocol Fx-006 or Fx-1A-201.~* Male or female subjects with ATTR-PN who had not undergone liver or heart transplantation at time of enrollment.~* If female, subject was post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control~Key Exclusion criteria:~* Chronic use of non-protocol approved non-steroidal anti-inflammatory drugs (NSAIDs)~* Pregnant or breast feeding female subjects.~* Clinically significant medical condition that, in the opinion of the investigator, would place the subject at an increased risk to participate in the study.~* An alanine aminotransferase (ALT) and aspartate aminotransferase (AST) value \>3 × upper limit of normal (ULN) that, in the medical judgment of the investigator, was due to reduced liver function or active liver disease.~* Sexually active males with partners of childbearing potential not using highly effective contraception or not agreeing to continue highly effective contraception for at least 3 months after last dose of study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open-Label (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic diagnosis of prostate cancer~* Favorable risk disease (cT1 or T2a, Gleason score (GS) 6, and Prostate Specific Antigen (PSA) \< 10 ng/mL)~* Low-tier intermediate risk disease (cT2c,GS=6,and PSA 10-15 ng/mL, OR GS=7 and PSA \< 10 ng/mL)~* Intermediate risk disease AND androgen deprivation therapy recommended by the treating physician for oncologic reasons such as (≥ 50% positive biopsy cores,cT2c,PSA 15-20 ng/mL,GS=7)~* Patient requires baseline planning trans-rectal ultrasound for the purposes of prostate brachytherapy, showing prostate volume \> 40 mL and pubic arch interference (not required for those requiring androgen ablation for oncologic reasons)~Exclusion Criteria:~* castrate serum testosterone level~* previous or concurrent pelvic radiotherapy~* unable to give written informed consent~* contraindications to permanent seed prostate brachytherapy or to androgen deprivation therapy~* prior treatment for prostate cancer~* prior trans-urethral resection of the prostate~* previous therapy with a 5-α reductase inhibitor, anti-androgen agent, or LHRH agonist~* previous therapy with degarelix

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Favorable prostate cancer with pubic arch interference (Type: EXPERIMENTAL): Men in this arm have chosen brachytherapy for management of localized prostate cancer and do not require androgen ablation for oncologic reasons but have an enlarged prostate causing pubic arch interference and thus require prostate size reduction prior to brachytherapy. They will have 2-3 months of Degarelix with measurement of prostate volume at 8 and 12 weeks.
- Intermediate risk prostate cancer, 6 months Degarelix (Type: EXPERIMENTAL): Men in this arm have higher risk prostate cancer (upper tier intermediate risk by National Comprehensive Cancer Network \[NCCN\] guidelines) and require 6 months of androgen ablation in conjunction with brachytherapy. Prostate size must be \> 40 cc at baseline so that prostate size reduction measurements are appropriate. Prostate measurements by transrectal ultrasound with be taken at 12 weeks and 20 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Subjects MUST:~1. Be able and willing to provide written informed consent and sign Health Information Portability and Accountability Act (HIPAA) form prior to any study procedure being performed;~2. Be able and willing to follow all instructions and attend study visits;~3. Be 45-75 years of age of either sex and any race or ethnicity at Visit 1;~4. Have +1.00 to -4.00 diopter (D) of sphere (so that SE results in myopia no more severe than -4.00 SE. See Inclusion 5 below) in both eyes determined by manifest refraction documented at Visit 1;~5. Have up to 2.00D of cylinder (minus cylinder) in both eyes determined by manifest refraction documented at Visit 1;~6. Be presbyopic as determined at Visit 1~Exclusion Criteria:~Subjects must NOT:~1. Be a female of childbearing potential who is currently pregnant, nursing or planning a pregnancy;~2. Have known contraindications or sensitivity to the use of any of the study medications(s) or their components;~3. Have an active ocular infection at Visit 1 (bacterial, viral or fungal), positive history of an ocular herpetic infection, preauricular lymphadenopathy, or ongoing, active ocular inflammation (e.g., moderate to severe blepharitis, allergic conjunctivitis, peripheral ulcerative keratitis, scleritis, uveitis) in either eye;~4. Have moderate or severe dry eye determined by total corneal fluorescein staining at Visit 1;~5. Have clinically significant abnormal lens findings (e.g., cataract) including early lens changes and/or any evidence of a media opacity in either eye during dilated slit-lamp biomicroscopy and fundus exam documented within 3 months of Visit 1;

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Combination ophthalmic solution (LNZ101) dosed bilaterally (Type: EXPERIMENTAL): LNZ101: Aceclidine/Brimonidine combination ophthalmic solution
- Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally (Type: EXPERIMENTAL): LNZ100: Aceclidine ophthalmic solution
- Vehicle Ophthalmic Solution dosed bilaterally (Type: EXPERIMENTAL): Proprietary Vehicle ophthalmic solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients with diagnosis of generalized anxiety disorder.~Exclusion Criteria:~* Any serious or uncontrolled medical condition.~* Current diagnosis of depression, dysthymia, obsessive-compulsive disorder.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete